Cathay Biotech Inc
SSE:688065
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cathay Biotech Inc
Total Assets
Cathay Biotech Inc
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Cathay Biotech Inc
SSE:688065
|
Total Assets
¥23.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Shanghai Putailai New Energy Technology Co Ltd
SSE:603659
|
Total Assets
¥46.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Wanhua Chemical Group Co Ltd
SSE:600309
|
Total Assets
¥328.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
21%
|
CAGR 10-Years
22%
|
|
|
Hoshine Silicon Industry Co Ltd
SSE:603260
|
Total Assets
¥86.1B
|
CAGR 3-Years
24%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
C
|
CNGR Advanced Material Co Ltd
SZSE:300919
|
Total Assets
¥81.6B
|
CAGR 3-Years
15%
|
CAGR 5-Years
53%
|
CAGR 10-Years
N/A
|
|
|
Tianqi Lithium Corp
SZSE:002466
|
Total Assets
¥72.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
11%
|
CAGR 10-Years
25%
|
|
Cathay Biotech Inc
Glance View
Cathay Biotech Inc. emerged from China's bustling metropolis of Shanghai, carving a niche in the realm of synthetic biology. Born in the late 1990s, the company set its sights on transforming the industrial landscape by harnessing the power of biomanufacturing. Cathay positioned itself as a leader in the production of long-chain diacid (LCDA) and bio-based polyamides, which are integral to a wide array of industries, including automotive, consumer electronics, and textiles. The company's core technology lies in advanced fermentation processes, where microorganisms are bioprocessed to produce these high-performance materials. These procedures not only reduce dependency on petrochemicals but also showcase the potential for sustainable innovations in industrial applications. Cathay Biotech monetizes its expertise by serving as a vital supplier for manufacturers worldwide, tapping into its patented technologies and scaling them to meet commercial demands. Its commitment to R&D has not only propelled the firm’s growth but also established long-term partnerships with key players across various sectors. Through its production facilities, Cathay has managed to fine-tune its microorganism strains and fermentation processes, leading to increased efficiencies and cost-effectiveness. This symbiotic relationship between innovation and commercialization at Cathay Biotech has allowed it to create a robust business model, drawing significant revenue from the sale of its bio-based products while consistently investing in technological advancements to expand its product portfolio.
See Also
What is Cathay Biotech Inc's Total Assets?
Total Assets
23.4B
CNY
Based on the financial report for Sep 30, 2025, Cathay Biotech Inc's Total Assets amounts to 23.4B CNY.
What is Cathay Biotech Inc's Total Assets growth rate?
Total Assets CAGR 5Y
16%
Over the last year, the Total Assets growth was 28%. The average annual Total Assets growth rates for Cathay Biotech Inc have been 11% over the past three years , 16% over the past five years .